Riggs Asset Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Riggs Asset Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-65	Closed	-$2.5K	–	440
2023 Q2	$2.5K	Hold	65	–	–	﹤0.01%	327
2023 Q1	$1.5K	Hold	65	–	–	﹤0.01%	308
2022 Q4	$1.7K	Hold	65	–	–	﹤0.01%	278
2022 Q3	$1K	Buy	+65	New	+$1.3K	﹤0.01%	318

Riggs Asset Management's KDNY Position: Q3 2023 in Review

Riggs Asset Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 65 shares — an estimated $2.5K sold.

Riggs Asset Management first reported a position in KDNY in Q3 2022 and held it in 4 quarters. The position peaked at $2.5K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Riggs Asset Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Riggs Asset Management sold 65 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $2.5K.
Riggs Asset Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
Riggs Asset Management's Chinook Therapeutics, Inc. Common Stock position peaked at $2.5K in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Riggs Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.